Credit Suisse Maintains Neutral on Cano Health, Lowers Price Target to $0.5
Portfolio Pulse from richadhand@benzinga.com
Credit Suisse analyst A.J. Rice has maintained a Neutral rating on Cano Health (NYSE:CANO) and lowered the price target from $2.5 to $0.5.
August 14, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cano Health's price target has been lowered by Credit Suisse from $2.5 to $0.5, while maintaining a Neutral rating.
The lowering of the price target by a significant margin indicates a less optimistic outlook for the company's stock in the short term. This could potentially lead to a decrease in the stock's price as investors adjust their expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100